WO2023180409A1 - Preparation d'immunoconjugués d'il2 - Google Patents

Preparation d'immunoconjugués d'il2 Download PDF

Info

Publication number
WO2023180409A1
WO2023180409A1 PCT/EP2023/057391 EP2023057391W WO2023180409A1 WO 2023180409 A1 WO2023180409 A1 WO 2023180409A1 EP 2023057391 W EP2023057391 W EP 2023057391W WO 2023180409 A1 WO2023180409 A1 WO 2023180409A1
Authority
WO
WIPO (PCT)
Prior art keywords
glycosylated
preparation
immunoconjugate
pharmaceutical preparation
cancer
Prior art date
Application number
PCT/EP2023/057391
Other languages
English (en)
Inventor
Paola BATTESTIN
Camilla BACCI
Alessandro REDI
Emiliano SANI
Ettore GILARDONI
Riccardo STUCCHI
Roberto DE LUCA
Cesare DI NITTO
Mattia MATASCI
Original Assignee
Philogen S.P.A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen S.P.A filed Critical Philogen S.P.A
Publication of WO2023180409A1 publication Critical patent/WO2023180409A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Definitions

  • the present invention relates to a preparation, in particular a pharmaceutical preparation, comprising a non-glycosylated IL2 immunoconjugate and a glycosylated IL2 immunoconjugate, wherein the percentage of the glycosylated IL2 immunoconjugate of the total IL2 immunoconjugate in the preparation is low, preferably 25% or lower.
  • the preparation has been shown to have an increased T cell activation activity relative to a preparation with a higher percentage of the glycosylated IL2 immunoconjugate.
  • the preparation finds application in the treatment of cancer in human patients.
  • L19-IL2 an immunoconjugates comprising human IL2 fused to antibody L19 (“L19-IL2”).
  • L19 (US patent n° 8,097,254) specifically binds the ED-B domain of fibronectin isoform B-FN, which is one of the best-known markers of angiogenesis.
  • ED-B is an extra domain of 91 amino acids found in the B-FN isoform.
  • ED-B accumulates around neovascular structures in aggressive tumours and other tissues undergoing angiogenesis, such as the endometrium in the proliferative phase and some ocular structures in pathological conditions but is otherwise undetectable in normal adult tissues.
  • L19-IL2 A number of uses of L19-IL2 have been previously described by the current applicants in W02007/115837, W02009/089858, WO2013/010749, WO2013/045125, WO2018/154517, WO2019/185792, W02020/070150, in particular its use in the treatment of human cancers, which are hereby incorporated by reference in their entirety.
  • non-glycosylated proteins can be obtained through recombinant expression in prokaryotic cells, this is not possible in the context of complex proteins such as L19-IL2, which forms a large 80 KDa non-covalent homodimer in solution.
  • the present inventors have devised a production method for the preparation of L19-IL2, which results in a high yield and, surprisingly, a low percentage of glycosylated L19-IL2 in the resulting preparation. Specifically, the percentage of glycosylated L19-IL2 in the preparation was reported to be between about 16.5% and 18.5%, with an average of 17% of the L19-IL2 being glycosylated ( Figure 4). In view of the high rates of glycosylation reported in the literature when IL2 was produced in eukaryotic cells (see discussion above), this was highly surprising. Previously described methods for producing the L19-IL2 conjugate had not provided any information on glycosylation levels (Carnemolla et. al. Blood (2002) 99, 1659).
  • L19-IL2 were compared with preparations comprising a high percentage of glycosylated L19- IL2 (“IPER L19-IL2”), the preparations with a low percentage of glycosylated L19-IL2 (“IPO L19- IL2”) unexpectedly resulted in superior T cell activation compared with preparations comprising a high percentage of glycosylated L19-IL2 (“IPER L19-IL2”) ( Figure 11). This was highly surprising in view of the literature which reported that a glycosylation of IL2 resulted in superior T cell activation (see discussion above).
  • the low percentage of glycosylated L19-IL2 in the preparation resulting from the production method devised by the present inventors is expected to have advantageous properties when used in the treatment of human patients compared with L19-IL2 preparations comprising higher percentages of glycosylated L19-IL2.
  • the advantageous properties include an increased T cell activation activity.
  • the present invention provides a preparation comprising:
  • a glycosylated IL2 immunoconjugate comprising human IL2 conjugated to an antibody molecule comprising the L19 complementarity determining regions (CDRs) set forth in SEQ ID NOs 1 to 6, and wherein the percentage of the glycosylated IL2 immunoconjugate is ⁇ 25% of the total IL2 immunoconjugate in the preparation.
  • CDRs complementarity determining regions
  • the antibody molecule in the IL2 immunoconjugate comprises the L19 VH domain set forth in SEQ ID NO: 7 and the L19 VL domain set forth in SEQ ID NO: 9. More preferably, the antibody molecule has the sequence of the L19 antibody in scFv format set forth in SEQ ID NO: 10. Most preferably, the IL2 immunoconjugate consists of or comprises the sequence of L19-IL2 set forth in SEQ ID NO: 13.
  • the IL2 is preferably human IL2. Most preferably, the IL2 has the sequence set forth in SEQ ID NO: 11.
  • the present invention provides a preparation comprising: (i) non-glycosylated L19-IL2; and
  • glycosylated L19-IL2 wherein the L19-IL2 comprises or consists of the sequence set forth in SEQ ID NO: 13; and wherein the percentage of glycosylated L19-IL2 is ⁇ 25% of the total L19-IL2 in the preparation.
  • the percentage of glycosylated IL2 immunoconjugate of the total IL2 immunoconjugate in the preparation is preferably ⁇ 25%, ⁇ 24%, ⁇ 23%, ⁇ 22%, ⁇ 21 %, ⁇ 20%, ⁇ 19%, or ⁇ 18.5%, with a lower % of glycosylation being preferred for the reasons explained above.
  • the percentage of glycosylated IL2 immunoconjugate of the total IL2 immunoconjugate in the preparation may be > 2%, > 5%, > 10%, or > 15%.
  • the percentage of glycosylated IL2 immunoconjugate of the total IL2 immunoconjugate in the preparation may be > 2% and ⁇ 20%.
  • the glycosylated IL2 immunoconjugate comprises an O-linked glycosylation at the serine at position 3 of IL2, wherein the IL2 has the sequence set forth in SEQ ID NO: 11.
  • the IL2 immunoconjugate is L19-IL2 and comprises or consists of the sequence set forth in SEQ ID NO: 13
  • the glycosylated L19-IL2 preferably comprises an O-linked glycosylation on the serine at position 256 of SEQ ID NO: 13.
  • the O-linked glycosylation may be linear or branched.
  • the O-linked glycosylation preferably comprises one core of HexoseN-acetyl-Hexosel plus 1 N-glycolyl neuraminic acid
  • the O-linked glycosylation preferably comprises one core of HexoseN-acetyl-Hexosel plus 2 N-glycolyl neuraminic acid residues. More preferably, the O-linked glycosylation is HexNAciHexiNeuGci or HexNAciHexiNeuGc2.
  • the O-linked glycosylation is Neu5Gca2-3Gaipi- 3GalNAcC1S(3)1 or Neu5Gca2-3Gaipi-3(Neu5Gca2-6)GalNAcC1S(3,6)2.
  • the IL2 immunoconjugate is not glycosylated at any other position in the IL2 sequence.
  • the present invention provides a preparation comprising:
  • a glycosylated IL2 immunoconjugate wherein the L19-IL2 comprises or consists of the sequence set forth in SEQ ID NO: 13, wherein the percentage of glycosylated L19-IL2 is ⁇ 20% of the total L19-IL2 in the preparation, and wherein the preparation has a higher T cell activation activity compared to a preparation in which the percentage of glycosylated L19-IL2 is 45% or more, preferably 45%, of the total L19-IL2 in the preparation.
  • the pharmaceutical preparation of the invention may further comprise, in addition to the active ingredient (glycosylated and non-glycosylated IL2 immunoconjugate), a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art and suitable for the administration to human patients. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
  • the pharmaceutical preparation may be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability
  • the pharmaceutical preparation of the invention may be for use in a method of treating cancer in a patient. Also provided is a method of treating cancer, the method comprising administering a therapeutically effective amount of the pharmaceutical preparation of the invention to the patient. Similarly provided is the use of the pharmaceutical preparation of the invention in the manufacture of a medicament for the treatment of cancer.
  • the patient is preferably a human patient.
  • Cancers that may be treated using a pharmaceutical preparation of the invention include solid cancers, such as skin cancer, renal cancer, pancreatic cancer, non-small cell lung cancer, diffuse large B cell lymphoma (DLBCL), basal cell carcinoma, or cutaneous squamous cell carcinoma.
  • solid cancers such as skin cancer, renal cancer, pancreatic cancer, non-small cell lung cancer, diffuse large B cell lymphoma (DLBCL), basal cell carcinoma, or cutaneous squamous cell carcinoma.
  • the invention includes the combination of the aspects and preferred features described except where such a combination is clearly impermissible or expressly avoided.
  • Figure 1 shows the general outline of the production process of L19-IL2 used to obtain the pharmaceutical preparation comprising a low percentage of glycosylated L19-IL2 of the invention.
  • Figure 2A bidimensional SDS-PAGE analysis of the pharmaceutical preparation comprising a low percentage of glycosylated L19-IL2 confirmed the purity of the sample after production, as well as the molecular weight ( ⁇ 42 KDa) and isoelectric point ( ⁇ 7.7) of L19-IL2. Three spots were visible: non-glycosylated L19-IL2 (spot 1), mono-glycosylated L19-IL2 (spot 2) and diglycosylated L19-IL2 (spot 3). Spot 1 (non-glycosylated L19-IL2) was the most intense, while spots 2 and 3 were barely visible, indicating the very low abundance of glycosylated L19-IL2 in the preparation.
  • B Purified milligrams of L19-IL2 per litre of fermentation culture recovered from five lots of production.
  • Figure 3 A shows the deconvoluted spectrum of the mass spectrometry analysis of a L19-IL2 preparation comprising a low percentage of glycosylated L19-IL2 prepared according to the method described herein.
  • the main peak (1) at 42022 Da corresponds to the non-glycosylated L19-IL2 protein
  • peak (2) at 42695 Da corresponds to the L19-IL2 variant with a glycan HexNAc1 Hex1 NeuGc1
  • peak (3) at 43001 Da corresponds to the L19-IL2 variant with a glycan HexNAc1Hex1 NeuGc2.
  • Other minor peaks are irrelevant: the small peak at 41978 Da is a typical MS artefact corresponding to L19-IL2 without one CO2 group.
  • the other small peak at 42120 Da corresponds to L19-IL2 coupled with a phosphate group of the buffer.
  • B shows the deconvoluted spectrum of the mass spectrometry analysis of a L19-IL2 preparation comprising a high percentage of glycosylated L19-IL2.
  • the peak (1) at 42022 Da corresponds to the non- glycosylated L19-IL2 protein
  • peak (2) at 42678 Da corresponds to the L19-IL2 variant with a glycan HexNAc1Hex1NeuAc1
  • peak (3) at 42970 Da corresponds to the L19-IL2 variant with a glycan HexNAc1Hex1 NeuAc2
  • peak (4) at 4335 corresponds to the L19-IL2 variant with a glycan HexNAc2Hex2NeuAc2.
  • Other minor peaks are irrelevant: the small peak at 41978 Da is a typical MS artefact corresponding to L19-IL2 without one CO2 group.
  • the other small peak at 42120 Da corresponds to L19-IL2 coupled with a phosphate group of the buffer.
  • Figure 4 A shows the percentage of non-glycosylated L19-IL2, mono-glycosylated L19-IL2 and di-glycosylated L19-IL2 of the total L19-IL2 in different production lots of the pharmaceutical preparation prepared using the method described herein. In five lots of production using the method described herein, glycosylated L19-IL2 never exceeded 20% of the total L19-IL2 in the preparation, with an average percentage of glycosylated L19-IL2 in the preparation of 17,06%.
  • B shows the percentage of non-glycosylated L19-IL2 and glycosylated L19-IL2 produced according to a standard protocol (i.e. not according to the claimed invention; included for comparative purposes only). In this case, non-glycosylated L19-IL2 and glycosylated L19-IL2 each formed 45-50% of the total L19-IL2 in the preparation.
  • Figure 5 shows the MS1 spectrum of the glycosylated peptide
  • VEIKEFSSSSGSSSSGSSSSGAPT(+HexNAc1Hex1 NeuGd )SSSTK in a representative lot of production of a L19-IL2 preparation comprising a low percentage of glycosylated L19-IL2. Detection of a 4+ charged ion at 853.6212 m/z is consistent with the presence of one additional NeuGc group on the HexNAd Hex1 core attached on the threonine at position 24 of the peptide, which corresponds to the threonine at position 256 in the L19-IL2 conjugate.
  • Figure 6 shows the MS2 spectrum of the glycosylated peptide VEIKEFSSSSGSSSSGSSSSGAPT(+HexNAc1 Hex1NeuGc1)SSSTK in a representative lot of production of a L19-IL2 preparation comprising a low percentage of glycosylated L19-IL2.
  • the precursor ion at 853.62 m/z was isolated and HCD fragmented to generate this MS2 spectrum.
  • the presence of two peaks at 290.08 m/z (NeuGd - H2O) and 308.09 m/z (NeuGd) confirms the presence of the NeuGc group on the peptide.
  • This data further confirms the correct identification of the HexNAd Hex1 NeuGd group on threonine at position 24 of the peptide, which corresponds to the threonine at position 256 in the L19-IL2 conjugate.
  • Figure 7 shows the MS1 spectrum of the glycosylated peptide VEIKEFSSSSGSSSSGSSSSGAPT(+HexNAc1Hex1NeuGc2)SSSTK in a representative lot of production of a L19-IL2 preparation comprising a low percentage of glycosylated L19-IL2. Detection of a 3+ charged ion at 1240.1882 m/z is consistent with the presence of two additional NeuGc groups on the HexNAd Hex1 core attached on the threonine at position 24 of the peptide, which corresponds to the threonine at position 256 in the L19-IL2 conjugate.
  • Figure 8 shows the MS2 spectrum of the glycosylated peptide VEIKEFSSSSGSSSSGSSSSGAPT(+HexNAc1Hex1 NeuGc2)SSSTK in a representative lot of production of a L19-IL2 preparation comprising a low percentage of glycosylated L19-IL2.
  • the precursor ion at 1240.18 m/z was isolated and HCD fragmented to generate this MS2 spectrum.
  • the presence of two peaks at 290.08 m/z (NeuGd - H2O) and 308.09 m/z (NeuGd) confirms the presence of additional NeuGc groups on the peptide.
  • FIGS 9A and B show a diagram describing the inoculum preparation and fermentation processes used to obtain a L19-IL2 preparation comprising a low percentage of glycosylated L19-IL2 (Upstream 1 and Upstream 2).
  • Figures 10A and B show a diagram describing the purification process steps used to obtain a L19-IL2 preparation comprising a low percentage of glycosylated L19-IL2 (Downstream 1 and Downstream 2).
  • Figure 11 shows a T cell activation assay comparing a L19-IL2 preparation comprising a low percentage of glycosylated L19-IL2 (“IPO L19IL2”) according to the invention with a L19-IL2 preparation comprising a high percentage of glycosylated L19-IL2 (“IPER L19IL2”) prepared using standard methods.
  • L19-IL2 preparation comprising a low percentage of glycosylated L19-IL2 shows superior T cell activation activity (EC504.3 pM) as compared to the L19-IL2 preparation comprising a high percentage of glycosylated L19-IL2 (EC50 9.5 pM).
  • the pharmaceutical composition of the present invention comprises an IL2 immunoconjugate, wherein the IL2 immunoconjugate comprises an antibody molecule comprising the L19 complementarity determining regions (CDRs) set forth in SEQ ID NOs 1 to 6 and IL2.
  • CDRs complementarity determining regions
  • the antibody molecule is preferably monoclonal.
  • the antibody molecule may be human or humanised, but preferably is a human antibody molecule.
  • the antibody molecule may be isolated, in the sense of being free from contaminants, such as antibodies able to bind other polypeptides, and/or serum components.
  • the antibody molecule may be natural or partly or wholly synthetically produced.
  • the antibody molecule may be a recombinant antibody molecule.
  • the antibody molecule may be an immunoglobulin, or an antigen-binding fragment thereof.
  • the antibody molecule may be an IgG, IgA, IgE or IgM molecule, preferably an IgG molecule, such as an lgG1, lgG2, lgG3 or lgG4 molecule, but more preferably is an antigenbinding fragment thereof.
  • the antibody molecule comprises or consists of a single-chain Fv (scFv), a small immunoprotein, a diabody, but most preferably is an scFv.
  • the antibody molecule preferably comprises the L19 VH domain set forth in SEQ ID NO: 7 and/or the L19 VL domain set forth in SEQ ID NO: 9. More preferably, the antibody molecule has the sequence of the L19 antibody in scFv format set forth in SEQ ID NO: 10.
  • the VH and VL domains of the antibody are preferably linked by a 12 to 20 amino acid linker.
  • the VH and VL domains may be linked by an amino acid linker which is 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid in length.
  • Suitable linker sequences are known in the art and include the linker sequence set forth in SEQ ID NO: 8.
  • the IL2 is preferably human IL2. Most preferably, the IL2 has the sequence set forth in SEQ ID NO: 11.
  • the antibody molecule e.g. scFv or IgG, and the IL2 may be connected to each other directly, for example through any suitable chemical bond, but preferably are connected via a peptide linker.
  • the chemical bond may be, for example, a covalent or ionic bond. Examples of covalent bonds include peptide bonds (amide bonds) and disulphide bonds.
  • the peptide linker may be a short (2-30, preferably 10-20) residue stretch of amino acids. Suitable examples of peptide linker sequences are known in the art. One or more different linkers may be used. An exemplary linker sequence is set forth in SEQ ID NO 12. In one embodiment, the linker may be a cleavable linker.
  • the conjugate may be produced (secreted) as a single chain polypeptide, such as a fusion protein.
  • the IL2 is conjugated to the C-terminus of the antibody molecule in scFv format.
  • the IL2 immunoconjugate consists of, or comprises, the sequence of L19-IL2 set forth in SEQ ID NO: 13.
  • the IL2 in the glycosylated IL2 immunoconjugate comprised in the pharmaceutical preparation of the invention preferably comprises an O-linked glycosylation on the serine at position 3 of the IL2 sequence set forth in SEQ ID NO: 11.
  • the glycosylated L19-IL2 preferably comprises an O-linked glycosylation on the serine at position 256 of SEQ ID NO: 13.
  • the glycosylated IL2 immunoconjugate is not glycosylated at any other position in the IL2 sequence.
  • the IL2 in the glycosylated IL2 immunoconjugate may be mono-glycosylated or di-glycosylated.
  • the O-linked glycosylation is preferably HexNAciHexiNeuGci, while in the di-glycosylated IL2 immunoconjugate, the O-linked glycosylation is preferably HexNAciHexiNeuGc2.
  • the pharmaceutical preparation of the invention will usually comprise both mono-glycosylated IL2 immunoconjugate and di- glycosylated IL2 immunoconjugate, in addition to non-glycosylated IL2 immunoconjugate.
  • the L19 in the glycosylated L19-IL2 immunoconjugate comprised in the pharmaceutical preparation of the invention is not glycosylated. That is, only the IL2 in the glycosylated L19-IL2 immunoconjugate comprised in the pharmaceutical preparation of the invention is glycosylated.
  • the percentage of glycosylated IL2 immunoconjugate of the total IL2 immunoconjugate in the pharmaceutical preparation of the invention is preferably ⁇ 25%, ⁇ 24.5%, ⁇ 24%, ⁇ 23.5%, ⁇ 23%, ⁇ 22.5%, ⁇ 22%, ⁇ 21.5%, ⁇ 21 %, ⁇ 20.5%, ⁇ 20%, ⁇ 19.5%, ⁇ 19%, or ⁇ 18.5%, with a lower % of glycosylation being preferred for the reasons explained above.
  • the % of glycosylation is ⁇ 20%.
  • the % of glycosylation is ⁇ 19.5%.
  • the % of glycosylation is ⁇ 19%.
  • the % of glycosylation is ⁇ 18.5%.
  • the percentage of glycosylated IL2 immunoconjugate of the total IL2 immunoconjugate in the preparation may be > 2%, > 3%, > 4%, > 5%, > 6%, > 7%, > 8%, > 9%, > 10%, > 11%, > 12%, > 13%, > 14%, > 15%, or > 16%. This excludes IL2 immunoconjugate preparations made in bacterial cells, which are not glycosylated.
  • the percentage of glycosylated IL2 immunoconjugate of the total IL2 immunoconjugate in the preparation may be > 2% and ⁇ 20%, > 2% and ⁇ 19.5%, > 2% and ⁇ 19%, or > 2% and ⁇ 18.5%.
  • the percentage of glycosylated IL2 immunoconjugate of the total IL2 immunoconjugate in the preparation may be > 5% and ⁇ 20%, > 5% and ⁇ 19.5%, > 5% and ⁇ 19%, or > 5% and ⁇ 18.5%.
  • the percentage of glycosylated IL2 immunoconjugate of the total IL2 immunoconjugate in the preparation may be
  • the pharmaceutical preparation of the invention may comprise, in addition to glycosylated and non-glycosylated IL2 immunoconjugate, as set out in the claims, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art and suitable for the administration to human patients.
  • the pharmaceutical composition may comprise a buffer composition as disclosed in W02018/011404.
  • the pharmaceutical composition may comprise glycosylated and non-glycosylated IL2 immunoconjugate, as set out in the claims, dissolved in a phosphate buffer comprising NaH2PC>4 at a concentration of 1-50 mM, NaCI at a concentration of 1-50 mM, KCI at a concentration of 1-2 mM, mannitol at a concentration of 50-200 mM, polysorbate80 at a concentration of 0.05-0.2% (v/v) or of 0.05-0.3%, glycerol at a concentration of 0.5-2% and have a pH from 5.5-7.0.
  • the phosphate buffer may further comprise and EDTA at a concentration of 1-20 mM but this is not preferred.
  • the NaH2PO4 may be present at a concentration within a range selected from the group consisting of: 2-25 mM, 3-20 mM, more preferably 5-15 mM. Most preferably the NaH2PO4 is present at 6.7 mM or about 6.7 mM.
  • the NaCI may be present at a concentration within a range selected from the group consisting of: 5-40 mM or 10-30 mM or more preferably 15-25 mM. Most preferably NaCI is present at 20 mM or about 20 mM.
  • the KCI may be present at a concentration within a range selected from the group consisting of: 1.2-2.0 mM, more preferably 1.5-1.8 mM. Most preferably, KCI is present at 1.8 mM or about 1.8 mM.
  • Mannitol may be present at a concentration within a range selected from the group consisting of: 80-180 mM, or more preferably 100-150 mM. Most preferably, mannitol is present at 133 mM or at about 133 mM.
  • Polysorbate80 may be present at a concentration within a range selected from the group consisting of (presented as v/v): 0.1 -0.3%, 0.07-0.18%, or more preferably 0.08-0.15%. The polysorbate80 may be present at 0.1% (v/v) or at about 0.1% (v/v). Preferably, polysorbate80 is present at 0.3% (v/v) or at about 0.3% (v/v).
  • Glycerol may be present at a concentration within a range selected from the group consisting of: 0.7-1 .8%, or more preferably 0.8-1 .5%. Most preferably, glycerol is present at 1 % (w/v) or about 1 % (w/v).
  • EDTA may be present at a concentration within a range selected from the group consisting of: 2-15 mM, or more preferably 3-10 mM or 6-9 mM. Most preferably EDTA is present at 5 mM or at about 5 mM.
  • the pH is preferably 6.0-6.8, more preferably 6.1-6.5 mM or 6.2-6.4. Most preferably, the pH is 6.3 or about 6.3. In a preferred embodiment, EDTA is absent.
  • the pharmaceutical preparation of the invention may comprise, in addition to glycosylated and non-glycosylated IL2 immunoconjugate as set out in the claims, 6.7 mM Na ⁇ PC , 20 mM NaCI, 1.8 mM KCI, 133 mM mannitol, 0.1 % polysorbate80 (v/v), 1 % glycerol (w/v) and 5mM EDTA and has pH 6.3.
  • the pharmaceutical preparation of the invention comprises, in addition to glycosylated and non-glycosylated IL2 immunoconjugate as set out in the claims, 6.7 mM NaH2PC>4, 20 mM NaCI, 1.8 mM KCI, 133 mM mannitol, 0.3% polysorbate80 (v/v), 1% glycerol (w/v) and has pH 6.3.
  • the pharmaceutical preparation of the invention comprises, in addition to glycosylated and non-glycosylated IL2 immunoconjugate as set out in the claims, 6.7 mM NaH2PC>4, 20 mM NaCI, 1.8 mM KCI, 133 mM mannitol, 0.1 -0.3% polysorbate80 (v/v), and 1% glycerol (w/v) and has pH 6.3.
  • the pharmaceutical preparation of the invention may comprise, in addition to glycosylated and non-glycosylated IL2 immunoconjugate as set out in the claims, about 6.7 mM NaH2PC>4, about 20 mM NaCI, about 1.8 mM KCI, about 133 mM mannitol, about 0.1 % polysorbate80 (v/v), about 1 % glycerol (w/v) and about 5 mM EDTA and has pH of about 6.3.
  • the pharmaceutical preparation of the invention may comprise, in addition to glycosylated and non-glycosylated IL2 immunoconjugate as set out in the claims, about 6.7 mM Na ⁇ PC , about 20 mM NaCI, about 1.8 mM KCI, about 133 mM mannitol, about 0.3% polysorbate80 (v/v), about 1% glycerol (w/v) and about 5 mM EDTA and has pH of about 6.3.
  • the pharmaceutical preparation of the invention may comprise, in addition to glycosylated and non-glycosylated IL2 immunoconjugate as set out in the claims, about 6.7 mM Na ⁇ PC , about 20 mM NaCI, about 1.8 mM KCI, about 133 mM mannitol, about 0.1 -0.3% polysorbate80 (v/v), and about 1% glycerol (w/v) and has pH of about 6.3.
  • the preparation of the invention has a higher T cell activation activity compared to a preparation in which the percentage of glycosylated L19-IL2 is 45% or more, preferably 45%, of the total L19-IL2 in the preparation.
  • T cell activation activity refers to the ability of an L19-IL2 preparation to enhance T cell proliferation.
  • the T cell activation activity of an L19-IL2 conjugate may be expressed in terms of the half maximal effective concentration (EC50).
  • the half maximal effective concentration is a measure of the effectiveness of a substance in inducing a specific biological or biochemical function.
  • the EC50 is a quantitative measure that indicates how much of an agonist is needed to increase the activity of a given biological process or component of a process such as an enzyme, cell, cell receptor or microorganism by half.
  • Methods of determining EC50 in vitro and in vivo are known in the art.
  • the EC50 may refer to the amount of L19-IL2 needed to increase the proliferation of a T cell population (e.g. a population of CTLL2 cells) by half.
  • the preparation of the invention preferably has a half maximal effective concentration (EC50) of at most 4.3 pM, 4.4 pM, 4.5 pM, 5 pM, 5.5 pM, or 6 pM, or a lower EC50.
  • the EC50 of a preparation such as an L19-IL2 preparation, in the context of enhancing proliferation of a T cell population, can be determined by a T-cell activity assay, such as a CTLL2 T-Cell activity assay e.g., as detailed in Example 5.
  • the pharmaceutical preparation of the invention may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.
  • Treatments involving the pharmaceutical preparation of the invention may include the administration of a second anti-cancer therapy.
  • a second anti-cancer therapy Many suitable anti-cancer therapies are known in the art.
  • L19-IL2 has been successfully used in anti-cancer therapy when administered in combination with stereotactic ablative radiotherapy (SABR), or with an anti-PD- 1 therapeutic, such as an anti-PD-1 antibody.
  • SABR stereotactic ablative radiotherapy
  • an anti-PD- 1 therapeutic such as an anti-PD-1 antibody.
  • Clinical trials for these combinations are ongoing.
  • Promising anti-cancer effects have also been reported for the combined administration of L19- IL2 and L19-TNFa (WO2018/011404). This is in addition to the anti-cancer effect demonstrated for L19-IL2 monotherapy.
  • the pharmaceutical preparation of the invention may be for use in a method of treating cancer in a patient, wherein the method further comprises administering a second anti-cancer therapeutic selected from the group consisting of: radiotherapy, preferably stereotactic ablative radiotherapy (SABR), a radiolabelled conjugate, preferably a Lutethium-177 labelled conjugate, a check-point inhibitor, such as an anti-PD-1 therapeutic, preferably an anti-PD-1 antibody, L19- TNFa, or L19-TNFa and an anti-PD-1 therapeutic to the patient.
  • SABR stereotactic ablative radiotherapy
  • a radiolabelled conjugate preferably a Lutethium-177 labelled conjugate
  • a check-point inhibitor such as an anti-PD-1 therapeutic, preferably an anti-PD-1 antibody, L19- TNFa, or L19-TNFa and an anti-PD-1 therapeutic to the patient.
  • Administration of the pharmaceutical preparation of the invention and the second anti-cancer therapy to the patient may be simultaneous or sequential, whereby simultaneous administration refer
  • the pharmaceutical preparation of the invention and the second anti-cancer therapy may be provided as a combined preparation but are preferably provided as separate preparations to permit either simultaneous or sequential administration. Where the treatment further involves radiotherapy, this will necessarily be administered separately from the pharmaceutical preparation of the invention, but administration may nonetheless be simultaneous.
  • pain relief drugs such as non-steroidal anti-inflammatory drugs (e.g. aspirin, paracetamol, ibuprofen or ketoprofen) or opiates such as morphine, or antiemetics.
  • non-steroidal anti-inflammatory drugs e.g. aspirin, paracetamol, ibuprofen or ketoprofen
  • opiates such as morphine, or antiemetics.
  • the pharmaceutical preparation of the invention may be injected parenterally.
  • the pharmaceutical preparation of the invention is injected at the site of the tumour, preferably by intratumoral injection.
  • Peritumoral injection e.g. local intradermal injection, is another suitable method for administering the pharmaceutical preparation of the invention locally to a tumour site.
  • the pharmaceutical preparation of the invention may be administered by infusion, e.g. intravenous infusion.
  • Cancer treatment according to the present invention may include complete eradication of the tumour.
  • the disappearance of any evidence of vital tumour after termination of the treatment represents complete treatment of the tumour.
  • Disappearance of the tumour may be determined when the tumour has no discernible volume or is no longer visible.
  • Treatment may comprise treatment to eradicate the tumour and prevent tumour regrowth.
  • Patients are preferably monitored during a follow-up period of at least one month, preferably at least six months or at least a year, after administration of the pharmaceutical preparation of the invention. Disappearance of the tumour, and lack of tumour regrowth, may be observed in the follow-up period. Absence of tumour regrowth may be observed.
  • the quantity of L19-IL2 administered through administration of the pharmaceutical preparation of the invention to the patient will depend on the size and nature of the tumour, among other factors. The determination of suitable doses is within the competence of the skilled practitioner. Suitable doses are disclosed in WO2018/011404. For example, the dose of L19-IL2 may be in the range of 20 pg - 3 mg, e.g.
  • the dose of L19-IL2 is in the range of 2 mg to 3 mg, for example 2 mg to 2.5 mg. Most preferably, the dose of L19-IL2 is 2.17 mg.
  • the dose of L19-IL2 can alternatively be stated in international units (III). 2.17 mg L19-IL2 equates to 13 million IU L19-IL2. These are examples only and different doses may be used.
  • the pharmaceutical preparation of the invention may for use in a method of treating cancer.
  • the cancer may be a solid tumor.
  • the cancer is selected from skin cancer, renal cancer, pancreatic cancer, non-small cell lung cancer, diffuse large B cell lymphoma (DLBCL), basal cell carcinoma, and cutaneous squamous cell carcinoma.
  • the cancer may be metastatic or non-metastatic.
  • the pharmaceutical preparation of the invention is preferably administered together with L19-TNFa.
  • the L19-TNFa preferably comprises or consists of the sequence set forth in SEQ ID NO: 14. Details of such a therapy are disclosed in WO2013/045125 and in W02018/011404, which are hereby incorporated by reference in its entirety.
  • the pharmaceutical preparation of the invention may be for use in a method of treating skin cancer, such as a malignant melanoma or nonmelanoma skin cancer, but preferably a malignant melanoma, in a patient, wherein the method further comprises administering L19-TNFa to the patient.
  • Administration may be by injection at the tumor site, in particular, by intra-tumoral injection.
  • patients may be treated with 13 million IU of L19-IL2 corresponding to 2.17 mg of L19-IL2 and with 400 pg of L19-TNFa once weekly for one to four weeks, e.g., for one, two, three or four consecutive weeks.
  • the dose may be administered as a single intra-tumoral injection, or a dose may be divided into multiple intratumoral injections, which are administered to the same tumor. In selected cases the dosage can be halved down to 1.08 mg of L19-IL2 and 200 pg of L19- TNFa.
  • a L19-IL2 preparation comprising a “low percentage” of glycosylated L19-IL2 refers to a preparation in which the percentage of glycosylated L19-IL2 is ⁇ 25% of the total L19-IL2 in the preparation.
  • a L19-IL2 preparation comprising a “high percentage” of glycosylated L19-IL2 refers to a preparation in which the percentage of glycosylated L19-IL2 is > 40% of the total L19-IL2 in the preparation.
  • Example 1 Method for producing a preparation of L19-IL2 comprising a low percentage glycosylated L19-IL2
  • the L19-IL2 production process consisted of a first Upstream phase, dedicated to cell culturing of cells stably expressing L19-IL2, and a second Downstream phase, dedicated to the recovery of the product by chromatographic purification.
  • FIG. 9A and B describes the inoculum preparation and fermentation processes of L19-IL2 (Upstream 1 and Upstream 2).
  • Upstream 1 and Upstream 2 are divided into several numbered working steps as reported in the following tables.
  • the cell culture of one Working Cell Bank vial suitable for the production of L19-IL2 was amplified first in T75/T150 (cm 2 ) square flasks containing 15-30 ml of medium in standard conditions (37°C, 5% CO2) and then in 1.7 m 2 roller bottles (37°C, 0.75 rpm) containing 500 ml of medium.
  • the cell culture was expanded up to a volume of 7 liters and to a cell concentration higher than 900.000 cells/ml with a viability higher than 70%.
  • CD Hybridoma medium ThermoFisher cat n.
  • Fermentation took place in a Biostat C 30 L bioreactor sterilized in situ and equipped with a gas mixer and a ring sparger aeration system.
  • the pH was controlled by a flow of CO2 and calibrated additions of sodium carbonate solution.
  • the agitation system was composed of a single marine impeller.
  • the temperature was controlled by a water jacket connected to a steam heat exchanger.
  • the working temperature was 37 ⁇ 0.01°C.
  • the concentration of the dissolved oxygen was maintained at a 38% ⁇ 2% air saturation value with a flow of air, nitrogen, and oxygen mixture.
  • the relative ratios of these three different gasses were controlled by the system management software through the gas mixer device of the bioreactor.
  • the partial pressure of each of the three gases was 0.95 atm.
  • the cell adaptation period started when the inoculum (7 L of cell culture in a sterile plastic bag) was added to the fresh medium in the bioreactor. During this period, the cell culture was added with glucose and L-ultra-glutamine at predefined time intervals and concentrations. The stirring speed was set at 80 ⁇ 5rpm. After 3-5 days, the bioreactor was split 1 :4, the harvest was discarded and replaced with the same volume of fresh medium. After 3-5 days, the cell culture was split again, this time with a ratio 1:5. 4.2 L of cell culture were left in the bioreactor, and supplemented with 16.8 L of fresh medium to reach an overall volume of 21 L. This passage closed the cell adaptation period. At the end of the cell adaptation period, the cell count typically reached a viable cell concentration between 3-4,000,000 cells/ml, with a productivity of 30-40 mg/L. The cell culture harvested during this phase was discarded without any further processing. Fed-batch Fermentation
  • the fed-batch fermentation started at the second cell culture splitting, through addition of 16.8 L of fresh medium to 4.2 L of cell culture used as inoculum, with a 1 :5 dilution factor.
  • the stirring speed was set at 88 ⁇ 5rpm.
  • the fed-batch fermentation lasted 10-11 days (depending on the cell viability); during this period, the cell culture was fed at regular intervals with both a solution of HyClone Cell Boost 3 35 g/L in Pro CHO5 medium, and L-ultraglutamine 200 mM.
  • the approximate feed pattern is reported in the following table.
  • the cell culture was aseptically sampled daily. At the end of the process, the total volume of solution added was approximately 10-12 L, therefore a volume of approximately 30-33 L of cell culture was harvested from the bioreactor. At the end of the fed- batch fermentation, the final harvest generally had -5,000,000 viable cells/ml with a productivity of -150 mg/L secreted protein in the medium.
  • the process described above can also be performed using two twin bioreactors Biostat C 30L. In this case, 4.2 L of the cell culture from the 1 :5 splitting of the first bioreactor are used as inoculum for the second one.
  • the semi-continuous cell adaptation period is not required for the second bioreactor, and the fed-batch fermentation can run simultaneously with the first bioreactor.
  • the Crude Harvest was collected, and cells were removed by dead end filtration (see “Microfiltration” below).
  • a complete fermentation run lasted a total of 18 days, excluding the washing and sterilization of the equipment, and produced a total harvest of - 60-65 L for both bioreactors.
  • 8 to 10 g of crude harvest were obtained from a fermentation run.
  • the Crude Harvest was clarified and sterilized with orthogonal filtration on single-use cartridge filters.
  • the clarification step was carried out with a Sartopure GF2, 0.65 pm, 0.6 m 2 cartridge filter, while further clarification and sterilization was obtained through a combined single-use SartobranP, 0.45/0.22 pm, 0.45 m 2 cartridge filter.
  • the harvested material was loaded into the filters with a peristaltic pump at a flow rate of 1-2 L/min. After filtration, 0.5 M EDTA solution pH 7.5 was added to the harvested material to reach a final EDTA concentration of 5 mM, obtaining the Clarified Bulk.
  • the Clarified Bulk was stored at 2-8°C for a maximum of 40 days until the next purification step.
  • FIG. 10A and B show the purification process steps used to obtain L19-IL2 (Downstream 1 and Downstream 2).
  • Downstream 1 and Downstream 2 are divided into several numbered working steps as reported below.
  • Downstream 1 and Downstream 2 steps required the preparation of several buffers used for the sanitization, equilibration, elution and washing of the columns.
  • Each buffer was prepared in a stainless-steel tank under mechanical stirring, and the pH was adjusted with 5 M NaOH or 5 M HCI. Buffers were then sterile filtered (by Sartolon filters, 0.22 pm, 0.2m2) and transferred into sterile bags or bottles by a peristaltic pump.
  • Protein A affinity chromatography was performed using a rmp Sepharose Fast Flow resin packed in a Vantage A-130 or A-180 column.
  • the rmp Sepharose Fast Flow resin was a low leakage, non-mammalian-based affinity resin designed for high purity separation of monoclonal and polyclonal antibodies.
  • the base matrix, Sepharose 4 Fast Flow was a highly cross-linked, 4% agarose derivative, containing five antigen binding domains.
  • the scFv (L19) moiety of L19- IL2 fusion protein binds to protein A immobilized on the resin.
  • the Vantage A-130 and the Vantage A-180 columns differ in the volume of resin which can be packed into the column, from 400mL to 700mL for Vantage A-130 and from 700mL to 1300 mL for Vantage A-180.
  • the column, resin and flow line of the chromatographic system were sanitized in place with a solution of Acetic acid 0.1 M / Ethanol 20 %. The contact time was 60 minutes. After the treatment, the system was equilibrated in PBS (NaH2PO4 H2O 50 mM; NaCI 150 mM, EDTA 5 mM, pH 7.5).
  • the L19-IL2 fusion protein was then eluted from the column with Gly/NaCI (Glycine 100 mM; NaCI 150 mM, EDTA 5 mM, pH 3.0).
  • Gly/NaCI Glycine 100 mM; NaCI 150 mM, EDTA 5 mM, pH 3.0.
  • the chromatographic run was conducted by monitoring the absorbance at 280 and 260 nm, conductivity, and pH.
  • the eluted sample underwent viral inactivation through incubation at pH 3.0 for 1 hour at room temperature.
  • glycerol to 1% w/v of final concentration was added (conditioning), obtaining the Semiprocessed product.
  • the O.D. (280nm) at this stage ranges between 1.0 and 1.7.
  • the Semiprocessed product was stored at -80°C.
  • the Cation Exchange Chromatography step separated the main L19-IL2 isoforms: monomer, homodimer, and trimer.
  • the form of interest was represented by the non-covalent homodimeric form of L19-IL2.
  • resin and flow line of the chromatographic system were sanitized in place with a solution of Sodium hydroxide 1M for 60 minutes. After sanification, the system was equilibrated in buffer “A” (Na2SO4 15 mM;
  • the ionic strength was regulated to 5-6 mS/cm through dilution 4:5 with Conditioning Solution (Na2SO4 100 mM; Na2HPO4-7H2O 100 mM, EDTA 5 mM, pH 7.20, 23.50 - 27.50 mS/cm), followed by a further dilution with water for injection 1 :4.
  • the pH was corrected to 6.00 ⁇ 0.10.
  • the product was then filtered with a cartridge filter SartobranP, 0.22 pm, 0.05 m2 (or 0.1 m2 according to the volume) into sterile plastic bags and loaded on the column at room temperature.
  • the column was then washed at 150 ml/min with 2 CV (2 litres) of buffer “A” (Na2SO4 15 mM;
  • the gradient applied can be divided into 2 different phases: 1 : 0-40% B in 10 CV and 2: 40-100% B in 0 CV.
  • the various L19-IL2 isoforms (monomer, homodimer, and trimer) eluted respectively at 9.5 - 14.0 mSi/cm (monomer), 15.0 - 19.0 mSi/cm (dimer), 19.0.- 21.0 mSi/cm (trimer).
  • the relative ratio of the various isoforms was usually in the range of 25%-35% monomer, 55%-65% homodimer and 3%-10% trimer.
  • L19-IL2 purified homodimer (Purification Intermediate 1) was filtered through a 0.22 pm sterile filter in glass bottles and stored at 2-8°C until the next process step. When all the runs of a batch were completed, the Purification Intermediates 1 were pooled before being processed by buffer exchange.
  • the buffer exchange process was performed using the Sartocon Slice cassette system (30kDa), a tangential filtration system based on the hydrophilic and neutral cellulose-based membrane Hydrosart with 30kDa cut-off. This system permits the transfer of L19-IL2 to the formulation buffer using several cycles of diafiltration. Before use, the cassette was washed with a 0.9% NaCI solution for 10 minutes and sanitized with a NaOH 1 M solution, recirculated for not less than 60 minutes, at 1.5 bar pressure.
  • the cassette was washed with 1 L of WFI, then equilibrated with formulation buffer (6.7 mM NaH2PO4, 1.8 mM KCI, 20 mM NaCI, 133 mM Mannitol, 1 % w/v Glycerol, pH 6.30) until pH and conductivity of the permeate match the values of the formulation buffer.
  • formulation buffer 6.7 mM NaH2PO4, 1.8 mM KCI, 20 mM NaCI, 133 mM Mannitol, 1 % w/v Glycerol, pH 6.30
  • the Purification Intermediate 1 passes through the slice cassette: the protein was retained and returns to the starting bottle (retentate), while the elution solution flows away as permeate. At the same time, the volume of permeate was replaced by a same amount of formulation buffer. When the conductivity and pH of retentate reach the same values as formulation buffer, the buffer exchange was completed and the Purified Sample was obtained.
  • the Anion Exchange Chromatography purification step was performed on Sartobind Q cartridge. It was a strong basic anion exchanger based on quaternary ammonium. Before loading the sample, the capsule was activated by pumping at least 200 ml of NaCI 1M, then NaOH 1M was flushed for at least 60 minutes to sanitize the capsule (supplied as non-sterile). Sartobind Q capsule was used in flow through mode, so that the L19-IL2 does not bind to the membrane and it was collected directly into the flow through container. The DNA potentially present in the sample was removed by binding to the Sartobind Q matrix. This chromatography resulted in the Purification Intermediate 3.
  • the purpose of the nanofiltration process was to remove any virus from the Purification Intermediate 3.
  • the nanofiltration was performed with a Pro Modus 1.1 or Pro Modus 1.2 Viresolve filter.
  • the filter was flushed with water for 10 minutes, sanitized flushing NaOH 0.5M for 1 hour and then equilibrated with formulation buffer.
  • the filtration flow rate was automatically adjusted by the AKTA Pilot system to keep a constant pressure.
  • the filtered material represents the Purification Intermediate 4 with an optical density between 0.800 and 1.000.
  • the purpose of the diafiltration process was to concentrate the Purification Intermediate 4 to reach an optical density between 2.100 and 2.400.
  • the concentration was performed using a 30kDa Sartocon slice cassette system.
  • the system can concentrate the Purification Intermediate 4 through several cycles of diafiltration; in this case the concentration factor was around 3.
  • the formulation buffer filtered through the slice cassette (permeate) was not replaced, while the protein was retained and returned to the starting bottle (retentate).
  • the cassette was washed with a 0.9% NaCI solution for 10 minutes and sanitized with a NaOH 1 M solution, recirculated for at least 60 minutes, at 1.5 bar pressure.
  • the cassette was washed with 1L of WFI, then equilibrated with formulation buffer until pH and conductivity of the permeate match the values of formulation buffer.
  • the concentration can start.
  • the permeate outlet was connected to the UV/pH/Conductivity monitors on the AKTA Pilot System, then the Inlet and the Retentate Outlet were connected to the three ways cap of the Sample Bottle.
  • the A280nm of the retentate was checked in process; the concentration process was stopped when the A280nm reaches a value of 2.250 ⁇ 0.150.
  • the Purified Bulk obtained at the end of this process, represented the Drug Substance.
  • the excipient Polysorbate 80 was concentrated to 0.3% v/v. 2 - Method for of L19-IL2 a to the claimed invention: included for
  • L19-IL2 was expressed by transient gene expression using the mammalian expression vector pcDNA3-L19-IL2 according to a standard method described below (i.e., not according to the claimed invention).
  • L19-IL2 was then purified by Protein-A affinity chromatography followed by a polishing step by Cation Exchange Chromatography (Cl EX). Briefly, the six days old supernatant from transfected cells was clarified by centrifugation and filtration before loading on HiTrapTM rProtein A Fast Flow column using an AKTA PURE chromatographic system.
  • the column was washed by 5 consecutive steps consisting of (1) 150mM NaCI, 50mM NaH 2 PO 4 , 5mM EDTA, 50mM NaOH, pH 7.5 (2) 650mM NaCI, 50mM NaH 2 PO 4 , 5mM EDTA, 53mM NaOH, pH 7.5 (3) 50 mM NaH 2 PO 4 , 150 mM NaCI, 1M Urea, 5 mM EDTA, 10% (v/v) Isopropanol, pH 7.5 (4) 250mM L-Arginine, pH 7.5 (5) 50mM Citric acid, pH4, before eluting the L19-IL2 sample with 50mM Citric acid, pH4.
  • the collected eluate was then further purified by Cl EX using a Source 30S resin as solid support.
  • the Protein-A purified L19-IL2 sample was conditioned by dilution with 2.5 volumes of MilliQ-H 2 O and 1.15 volumes of 100mM Na 2 SO 4 , 100mM Na 2 HPO 4 , 5mM EDTA, pH 7.2, before loading on a Source 30S column.
  • the loaded L19-IL2 was then eluted using a 0-40% gradient from Buffer A (15mM Na 2 SO 4 , 15mM Na 2 HPO 4 , 5mM EDTA, pH6) to Buffer B (15mM Na 2 SO 4 , 15mM Na 2 HPO 4 , 5mM EDTA, 0.5M NaCI, pH6).
  • Buffer A 15mM Na 2 SO 4 , 15mM Na 2 HPO 4 , 5mM EDTA, 0.5M NaCI, pH6
  • Buffer B 15mM Na 2 SO 4 , 15mM Na 2 HPO 4 , 5mM EDTA, 0.5M NaCI, pH6.
  • MS1 scan range was set from 350 to 1650 m/z, the 10 most abundant peptides were subjected to HCD fragmentation with NCE of 25. A dynamic exclusion was set at 10 seconds.
  • Raw files were processed with Proteome Discoverer 1.4. Database searches were performed using Sequest as search engine using a FASTA file containing our protein of interest, the mus musculus reference proteome and additional contaminants (human keratin isoforms, bovine serum albumin and ProteinA from Staphylococcus Aureus).
  • the preparations comprising a high percentage of glycosylated L19-IL2 were compared with those comprising a low percentage of glycosylated L19-IL2 in a T cell proliferation assay.
  • the assay is based on a colorimetric method for determining the number of viable cells in proliferation.
  • CTLL-2 cell line is a clone of cytotoxic T cells which are IL2 dependent for growth, and which are routinely used to assay the activity of IL2 and IL2 conjugates such as L19-IL2.
  • CTLL2 cells were grown in RPMI-1640 medium (Gibco; 21875-034), supplemented with 10% FBS and 2mM L-Glutamine. Fresh 10% T-STIM with ConA was added at each passage. Cells were cultured in 20mL culture medium in a T-75 flask maintained at 37°C and 5%CO2. Cells were kept at a density between 0.1-0.5mio/mL.
  • Step 1 Cells were counted (e.g., 20mL at 0.4mio/mL), spun for 5 minutes at 900rpm, and then washed with 50m L of culture medium.
  • Step 2 Cells were spun for 5 minutes at 900rpm, and then washed with 50mL of culture medium.
  • Step 3 Cells were spun for 5 minutes at 900rpm, before being resuspended at the initial concentration in 20mL of culture medium.
  • Step 4 Cells were incubated at 37°C and 5%CC>2 for 24 hours.
  • Step 1 Cells were spun for 5 minutes at 900rpm, and then washed with 50mL of culture medium.
  • Step 2 Cells were spun for 5 minutes at 900rpm, before being resuspended in culture medium at a concentration of 0.5mio/mL.
  • Step 3 50pL of cells were added per well (i.e. , 25’000 cells/well) in a 96-well plate.
  • Step 4 50pL of protein samples, diluted in culture medium according to a serial dilution scheme, were added to each well.
  • Step 5 Cells were incubated at 37°C and 5%CC>2 for 48 hours.
  • Step 1 20pL of CellTiter Aqueous One Solution was added per well and the cells were incubated at 37°C and 5%CO2.
  • Step 2 Absorbance was measured at 490nm vs 620nm at the following timepoints: 1 h, 2h, 3h and 4h.
  • Step 1 The medium only background was subtracted from all samples’ absorbance data.
  • Step 2 Data was normalized using the formula: (sample - average cells only) I average cells only.
  • Threonine 3 is shown in bold, italics and underlined
  • Threonine 256 is shown in bold, italics and underlined
  • Serine 257 is shown in bold, italics and underlined

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une préparation, en particulier une préparation pharmaceutique, comprenant un immunoconjugué d'IL2 non glycosylé et un immunoconjugué d'IL2 glycosylé, le pourcentage d'immunoconjugué d'IL2 glycosylé rapporté au total d'immunoconjugué d'IL2 dans la préparation étant faible, de préférence de 25 % ou moins. La préparation trouve une application dans le traitement du cancer chez des patients humains.
PCT/EP2023/057391 2022-03-23 2023-03-22 Preparation d'immunoconjugués d'il2 WO2023180409A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22163911.5 2022-03-23
EP22163911 2022-03-23

Publications (1)

Publication Number Publication Date
WO2023180409A1 true WO2023180409A1 (fr) 2023-09-28

Family

ID=80930296

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/057391 WO2023180409A1 (fr) 2022-03-23 2023-03-22 Preparation d'immunoconjugués d'il2

Country Status (1)

Country Link
WO (1) WO2023180409A1 (fr)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5417970A (en) 1988-10-21 1995-05-23 Sanofi Drugs containing a glycosylated interleukin-2
WO2001062298A2 (fr) 2000-02-24 2001-08-30 Philogen S.R.L. Compositions et procedes de traitement de l'angiogenese dans des lesions pathologiques
WO2007115837A2 (fr) 2006-04-07 2007-10-18 Bayer Pharma Schering Aktiengesellschaft Combinaison d'une protéine de fusion à anticorps anti-domaine ed-b de fibronectine et à il-2, et de gemcitabine
WO2009089858A1 (fr) 2008-01-17 2009-07-23 Philogen S.P.A. Association d'une protéine de fusion il-2-anticorps anti-edb de fibronectine, et d'une molécule se liant aux lymphocytes b, aux cellules progénitrices des lymphocytes b et/ou leur contrepartie cancéreuse
US8097254B2 (en) 1998-05-11 2012-01-17 Eidgenossische Technische Hochschule Zurich Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
WO2013010749A1 (fr) 2011-07-19 2013-01-24 Philogen S.P.A Thérapie séquentielle il-2 anti-ctla4 et ciblée
WO2013045125A1 (fr) 2011-09-26 2013-04-04 Philogen S.P.A. Polythérapie par immunocytokine
WO2018011404A1 (fr) 2016-07-15 2018-01-18 Philogen S.P.A Compositions d'anticorps
WO2018154517A1 (fr) 2017-02-24 2018-08-30 Philogen Spa Polythérapie par immunocytokine
WO2019185792A1 (fr) 2018-03-29 2019-10-03 Philogen S.P.A Traitement du cancer à l'aide d'immunoconjugués et d'inhibiteurs du point de contrôle immunitaire
WO2020070150A1 (fr) 2018-10-02 2020-04-09 Philogen S.P.A Immunoconjugués d'il2

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5417970A (en) 1988-10-21 1995-05-23 Sanofi Drugs containing a glycosylated interleukin-2
US8097254B2 (en) 1998-05-11 2012-01-17 Eidgenossische Technische Hochschule Zurich Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
WO2001062298A2 (fr) 2000-02-24 2001-08-30 Philogen S.R.L. Compositions et procedes de traitement de l'angiogenese dans des lesions pathologiques
WO2007115837A2 (fr) 2006-04-07 2007-10-18 Bayer Pharma Schering Aktiengesellschaft Combinaison d'une protéine de fusion à anticorps anti-domaine ed-b de fibronectine et à il-2, et de gemcitabine
WO2009089858A1 (fr) 2008-01-17 2009-07-23 Philogen S.P.A. Association d'une protéine de fusion il-2-anticorps anti-edb de fibronectine, et d'une molécule se liant aux lymphocytes b, aux cellules progénitrices des lymphocytes b et/ou leur contrepartie cancéreuse
EP2085095A1 (fr) * 2008-01-17 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Combinaison de protéine de fusion anticorps de fibronectine anti-EDb-IL-2, et molécule se liant aux lymphocytes B, progéniteurs de lymphocytes B et/ou leur contrepartie cancéreuse
WO2013010749A1 (fr) 2011-07-19 2013-01-24 Philogen S.P.A Thérapie séquentielle il-2 anti-ctla4 et ciblée
WO2013045125A1 (fr) 2011-09-26 2013-04-04 Philogen S.P.A. Polythérapie par immunocytokine
WO2018011404A1 (fr) 2016-07-15 2018-01-18 Philogen S.P.A Compositions d'anticorps
WO2018154517A1 (fr) 2017-02-24 2018-08-30 Philogen Spa Polythérapie par immunocytokine
WO2019185792A1 (fr) 2018-03-29 2019-10-03 Philogen S.P.A Traitement du cancer à l'aide d'immunoconjugués et d'inhibiteurs du point de contrôle immunitaire
WO2020070150A1 (fr) 2018-10-02 2020-04-09 Philogen S.P.A Immunoconjugués d'il2

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FERRARA ET AL., FEBS LETTERS, vol. 226, 1987, pages 47
LEEPENIESSEEBERGER, NATURE BIOTECHNOL., vol. 32, 2016, pages 443
PAWELEC ET AL., IMMUNOBIOLOGY, vol. 174, 1987, pages 67
PLANINC ET AL., ANALYTICA CHIMICA ACTA, vol. 13, 2016, pages 27
SCHLIEMANN CHRISTOPH ET AL: "Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 113, no. 10, 1 March 2009 (2009-03-01), pages 2275 - 2283, XP009139092, ISSN: 0006-4971, [retrieved on 20081112], DOI: 10.1182/BLOOD-2008-05-160747 *

Similar Documents

Publication Publication Date Title
RU2736339C1 (ru) Слитый белок человеческого фактора свертывания IХ (FIX), способ его получения и применения
AU2004309063B2 (en) Fc-erythropoietin fusion protein with improved pharmacokinetics
EP2576615B1 (fr) Protéines d'échafaudage à base de fibronectine ayant une stabilité améliorée
EP2763689B1 (fr) Variants du facteur de croissance 21 du fibroblaste
US20050202538A1 (en) Fc-erythropoietin fusion protein with improved pharmacokinetics
CN109498815B (zh) 重组人激肽释放酶的化学修饰物及其应用
EP3400241B1 (fr) Modulation d'espèces afucosylées dans une composition d'anticorps monoclonal
CA2891190A1 (fr) Conjugues polypeptide derive d'aprotinine-anticorps
AU2017206012A1 (en) Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
WO2021085518A1 (fr) Composition pharmaceutique aqueuse contenant une protéine de fusion d'albumine sérique et d'hormone de croissance
US20220331430A1 (en) Camphorsulfonic acid and combinations thereof with cationic excipients as viscosity reducing agents in high concentrated protein formulations
WO2023180409A1 (fr) Preparation d'immunoconjugués d'il2
WO2021075526A1 (fr) Procédé de production d'une protéine de fusion de sérum-albumine et d'hormone de croissance
WO2023180341A1 (fr) PRÉPARATION D'IMMUNOCONJUGUÉS DE TNFα
US11324802B2 (en) C3 fusion protein and methods of making and using thereof
US20220251502A1 (en) Methods for reducing the oxidation level of cysteine residues in a secreted recombinantly-expressed protein during cell culture
US20220033454A1 (en) Interleukin-22 fusion proteins, and their pharmaceutical compositions and therapeutic applications
CN114832102A (zh) 一种稳定的抗egfr抗体组合物
US20240092883A1 (en) Methods of purifying ranibizumab or a ranibizumab variant
CN115300623A (zh) 抗egfr融合蛋白或其抗原结合片段的组合物及其用途
WO2024058730A1 (fr) Fragments de scfv anti-angiogéniques stables et puissants et leurs utilisations comme antagonistes de vegf

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23712914

Country of ref document: EP

Kind code of ref document: A1